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Abstract
Canonical Wnt/b-catenin signaling has been suggested to promote self-renewal of pluripotent mouse and human
embryonic stem cells. Here, we show that SB-216763, a glycogen synthase kinase-3 (GSK3) inhibitor, can maintain mouse
embryonic stem cells (mESCs) in a pluripotent state in the absence of exogenous leukemia inhibitory factor (LIF) when
cultured on mouse embryonic fibroblasts (MEFs). MESCs maintained with SB-216763 for one month were morphologically
indistinguishable from LIF-treated mESCs and expressed pluripotent-specific genes Oct4, Sox2, and Nanog. Furthermore,
Nanog immunostaining was more homogenous in SB-216763-treated colonies compared to LIF. Embryoid bodies (EBs)
prepared from these mESCs expressed early-stage markers for all three germ layers, and could efficiently differentiate into
cardiac-like cells and MAP2-immunoreactive neurons. To our knowledge, SB-216763 is the first GSK3 inhibitor that can
promote self-renewal of mESC co-cultured with MEFs for more than two months.
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Introduction
Pluripotent embryonic stem cells (ESCs) have potential use in
regenerative medicine because they can differentiate into cell types
from all three germ layers. The quality of ESCs is critical for their
long-term maintenance and efficient differentiation into desired
lineages. Thus, identification of novel drugs that promote ESC
pluripotency and self-renewal is of great interest to the fields of
stem cell biology and regenerative medicine [1–3]. The classic
method for maintenance of mouse ESC (mESC) pluripotency is by
supplementation of medium with leukemia inhibitory factor (LIF)
[4–6]. In contrast to mESCs, most human ESC (hESC) lines are
thought to be epiblast-like and require basic fibroblast growth
factor-2 (FGF2) to retain their pluripotent state [3,7]. However,
reprogramming of human fibroblasts into induced pluripotent
stem cells in the presence of LIF yields hESCs that are LIF-
dependent and comparable to ground state mESCs [8]. LIF
maintains pluripotency in stem cells by parallel induction of Sox2
and Nanog through Klf4 and Tbx3, respectively, and downstream
activation of Oct4 [9]. Activation of the ‘‘trinity’’ factors – Oct4,
Sox2 and Nanog – is central to maintenance of pluripotency
[3,7,9–12]. However, other signal transduction pathways, includ-
ing the canonical Wnt pathway, can also activate these core
pluripotency-enabling transcription factors [1–3,13,14].
Wnt pathways are critical for developmental processes including
self-renewal, cell proliferation, lineage specification, and mainte-
nance of adult stem cells in a multipotent state [15–18]. The
canonical Wnt pathway is activated when canonical Wnt glycopro-
teins bind a membrane-associated receptor complex containing
frizzled (Fzd) and LRP family receptors [18–21]. Wnt binding
activates Disheveled (Dvl), which then inhibits a second complex
knownastheb-catenindegradationcomplex[20,21].Theb-catenin
degradationcomplexiscomprisedofaxin,glycogensynthasekinase-
3 (GSK3), and adenomatous polyposis coli (APC) [20,21].
Normally, the transcriptional co-activator b-catenin is recruited to
the axin-GSK3 complex by APC, where b-catenin is phosphory-
lated by GSK3 and targeted for proteosomal degradation [20–22].
Both isoforms of GSK3– GSK3a and GSK3b – are able to form a
complex with APC and axin to phosphorylate b-catenin [23–25].
When the canonical Wnt pathway is activated, b-catenin can
translocate to the nucleus to promote gene expression through
transcriptionfactor/lymphoidenhancer-bindingfactor(TCF/LEF)
response elements [17,18,21]. When b-catenin is not present in the
nucleus, TCF3 bound to TCF/LEF sites inhibits expression of
variouspluripotencytargetgenesthroughitsinteractionswithOct4,
Sox2, and Nanog transcription factors [26,27]. When b-catenin
doesbecomeavailableinthenucleus,itbindstoTCF3andalleviates
TCF3’s repression of pluripotency promoting genes [26–32]. This
b-catenin mediated expression of pluripotency genes is further fine-
tuned by co-regulators, other TCFs, and the trinity transcription
factors [14,27,33].
Another direct target of the b-catenin/TCF3 heterodimer is
the orphan nuclear receptor Lrh-1 [13]. b-catenin-deficient
mESCs have lower expression of Lrh-1, Oct4 and Nanog, and
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Oct4 and Nanog [13]. The existence of the Lrh-1 pathway
further supports the idea that b-catenin is critical for pluripo-
tency. Consistent with this interpretation, mESCs lacking both
isoforms of GSK3 express Oct4 and Nanog for an extended
period of time and fail to differentiate [25,32,33]. Despite the
strong genetic evidence in support of b-catenin’s role, no known
pharmacological agent that can stabilize b-catenin has been
shown to maintain pluripotency by itself for more than a week
[1,2,33–36]. Here, we report that 6-bromoindirubin-39-oxime
(BIO), CHIR-99021, and SB-216763 effectively activate b-
catenin mediated transcription, but only SB-216763 can main-
tain mESCs co-cultured with MEFs in a pluripotent state in the
absence of exogenous LIF for up to two months.
Materials and Methods
Cell Culture
CF-1 mouse embryonic fibroblasts (MEF; SCRC-1040, ATCC)
were used as a feeder layer for mESC cell culture. J1 mESC
(SCRC-1010, ATCC) and MilliTrace Nanog GFP Reporter
mESC (SCR089, Millipore) cell lines were cultured on MEFs
that were mitotically inactivated using 10 mg/mL mitomycin C
(Sigma). MESCs were cultured in DMEM (Mediatech) supple-
mented with 1.0 mM non-essential amino acids (NEAA), 0.1 mM
b-mercaptoethanol (Sigma), 1% penicillin/streptomycin (MP
Biomedicals), and 15% ESC qualified fetal bovine serum (ES-
FBS; SCRR-30-2020, ATCC). As indicated, the medium also
contained 1,000 U/mL mouse LIF (ESG1107, Chemicon),
various concentrations of SB-216763 (BIOMOL International),
BIO (Cayman Chemical), and CHIR-99021 (Cayman Chemical)
dissolved in 0.1% DMSO, or no supplements [referred to as LIF-
free or LIF (-)]. Cells were incubated at 37uC with 5% CO2 in a
Sanyo MCO18AICUV cell culture incubator. Media were
exchanged every two days. The mESC cultures were passaged
every 3–4 days at densities needed to yield 5% confluent mESC
cultures on the day of passaging (generally, between 1:4 and 1:8
dilutions). To minimize the carry-over of MEFs, the cultures were
treated with 0.25% trypsin for 50 seconds in the incubator.
Trypsin was quenched with ES-FBS-containing medium (without
any supplements) and removed from the sample by centrifugation
and resuspension of mESCs in the treatment-containing medium.
HEK293 cells (human embryonic kidney cell line; CRL-1573,
ATCC) were cultured in DMEM supplemented with 1%
penicillin/streptomycin and 10% bovine growth serum (HyClone).
Cells were incubated at 37uC with 5% CO2. Cultures were
passaged every 3 days.
The cells were monitored using either an Olympus CKX41
inverted microscope with stop-contrast objectives or an Olympus
IX51 inverted microscope equipped with Hoffman Modulation
Contrast system. Optical sectioning provided by the Hoffman
Modulation Contrast system eliminated the ‘‘halo’’ around the
mESC colonies. Pictures were captured using a digital, color CCD
Infinity2 camera and the software provided by the manufacturer
(Lumenera).
Super TOPFlash Reporter Assay
J1 mESCs were electroporated with reporter genes using the
NEON Transfection System according to the manufacturer’s
protocol (Life Technologies). The day before electroporation of J1
mESCs, mitomycin C inactivated MEFs were plated at 12,000
cells/well in white, clear-bottom 96-well assay plates (Costar
3610). The following day, 1610
6 J1 mESCs were electroporated
with 4.5 mg of Super TOPFlash (a b-catenin reporter with 7
concatenated TCF/LEF response elements upstream of firefly
luciferase [37]; Addgene plasmid 12456), and 0.5 mg of pGL4.73
Renilla luciferase control reporter (Promega) in 100 mL NEON tips
using a 1400 v, 10 ms pulse width, pulse number 3 setting.
Electroporated J1 cells were plated on the MEFs at 5,000 cells/
well in antibiotic-free mESC media supplemented with LIF. The
next day, the mESC-MEF co-cultures were treated with vehicle
(0.1% DMSO) or various doses of LIF, SB-216763, BIO, and
CHIR-99021 in LIF-free mESC medium. The cells were lysed 24
hours later with Passive Lysis Buffer (Promega) and reporter
activity was quantified using the Dual Luciferase Assay (Promega)
in a GLOMAX 96 Microplate Luminometer equipped with dual
injectors (Promega). The firefly data were normalized to Renilla
luciferase activity and then to the vehicle control.
HEK293 cells were also transfected using the NEON Trans-
fection System. Approximately 5610
6 HEK293 cells were
electroporated with 9 mg of Super TOPFlash and 1 mgo f
pGL4.73 in 100 mL NEON tips using a 1100 v, 20 ms pulse
width, pulse number 2 setting. Electroporated cells were diluted in
antibiotic-free HEK293 medium and then plated at 20,000 cells/
well in 96-well plates (Costar 3610). After 24 hours, treatments,
cell lysis, and luciferase quantification were carried out as
described for J1 mESCs, with the exception that all treatments
were performed in serum-free Opti-MEM.
MESC Pluripotency Assay
J1 mESCs or MilliTrace Nanog GFP Reporter mESCs were
passaged in 6-well plates as described above. LIF-free mESC
medium was supplemented with the indicated treatment immedi-
ately prior to culturing. MESCs for all conditions originated from
cultures maintained with LIF. Passaging occurred in parallel for all
treatments at regular intervals as determined by the fastest
growing culture. Subcultures were prepared by seeding 20,000–
50,000 cells/well in 6-well plates. The morphology of the J1
mESC cultures was monitored two days after passaging. Individual
colonies were then rated according to the degree of compactness,
circular shape, and the size of individual cells within the colony.
The number of total colonies and pluripotent-like colonies were
counted in five non-overlapping fields encompassing more than
25% of the well area (from one edge of the well to the opposite
edge). The J1 mESCs maintained with the indicated supplements
were (a) immunostained for Nanog and Oct4, (b) stained for
Alkaline Phosphatase activity according to manufacturer’s proto-
col (AP Staining Kit II, Stemgent), (c) assayed for expression of
pluripotency markers by quantitative PCR, or (d) differentiated
into cardiac-like cells and neurons as described below.
For the MilliTrace Nanog GFP Reporter mESCs, forty colonies
were scored based on the intensity and homogeneity of GFP
expression in each colony. Briefly, the highest score was assigned
to colonies that were thoroughly and intensely fluorescent. The
colonies that had incomplete labeling were scored based on the
approximate percentage of the colony that was intensely
fluorescent. Because MilliTrace Nanog GFP Reporter mESCs
continued to express low levels of GFP after one month of culture
in LIF-free conditions, the score for the LIF-free samples was
subtracted from the score for all samples.
Neuronal Differentiation
MESCs maintained with LIF or 10 mM SB-216763 for more
than a month were directed to differentiate into neurons using the
42/4+ protocol [38]. MESCs were grown in 0.1% gelatin-coated
6-well plates in the indicated medium for 2 days. The mESC-
enriched cultures were then trypsinized and two million mESCs
were plated on Petri dishes in embyroid bodies (EB) formation
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mercaptoethanol, 1% penicillin/streptomycin, and 10% ES-FBS).
Free-floating EBs were incubated 4 days with a single exchange of
medium after 2 days. The medium was then exchanged with EB
formation medium supplemented with 0.5 mM all-trans retinoic
acid (atRA; BIOMOL International) and EBs were incubated for
4 more days with a single exchange of medium after 2 days. These
induced neural precursor cells were seeded on a tissue culture plate
coated with poly-L-ornithine (MP Biomedicals) and laminin
(Sigma) in EB formation medium without atRA for 2 weeks.
Medium was exchanged every other day during this period. The
cultures were then immunostained for MAP-2.
Cardiac-like Differentiation
MESCs maintained with LIF or 10 mM SB-216763 for more
than a month were resuspended at 40,000 cells/mL in LIF-free
mESC medium. EBs were prepared by a hanging drop procedure.
Briefly, 20 mL drops containing mESCs were pipetted on the
inside of a 10-cm Petri dish lid. The lids were placed onto Petri
dishes containing 10 mL of HBSS and the EBs were allowed to
form and grow for 4 days in the incubator. After 4 days, 15–20
EBs were transferred to a well containing LIF-free mESC medium
in a 24-well plate. The medium was exchanged every two days and
autonomously beating cell aggregates were observed and counted.
Immunocytochemistry
Cells were fixed with cold 4% paraformaldehyde in PBS for 15
minutes at room temperature and then permeabilized with 0.1%
Triton-X 100 in PBS for 30 minutes. Serum blocking of non-
specific epitopes was carried out with 1% normal goat serum in
0.1% Triton-X 100/PBS for 30 minutes. Samples were incubated
with primary antibodies overnight at 4uC and then washed 5 times
with PBS for 5 minutes each. Secondary antibody was incubated
for 1 hour at room temperature, followed by PBS washes as
described above. MESC pluripotency was assessed with antibodies
for pluripotency-specific markers Nanog (Abcam; ab21603; 1:500)
or Oct–4 (Abcam ab19857; 1:1000). Neuronal differentiation was
confirmed by staining for the neuronal-specific marker MAP-2
(Santa Cruz Biotechnology; sc-20172; 1:1000). Alexa Fluor 488
goat anti-rabbit IgG was used as the secondary antibody against all
the primary antibodies (Life Technologies; A11008, 1:500).
Fluorescent images were captured with an Olympus IX51 inverted
microscope equipped with Infinity2 CCD camera system or a
Leica Microsystems inverted confocal microscope.
Quantitative PCR for Pluripotency-specific Genes and
Germ Line Markers
Total RNA was extracted from all samples using TRIzol
reagent (Life Technologies). RNA was extracted from mESCs that
were continuously cultured with LIF or 10 mM SB-216763 for one
month. RNA from EBs was isolated 4 days after EB formation.
RNA from cardiac-like cells was extracted six days after EBs were
seeded on tissue culture dishes (when the number of autonomously
contracting clusters had peaked). RNA from cultures directed to
differentiate into neurons was extracted four days after atRA was
added to the cultures.
First strand cDNA was synthesized with MMLV reverse
transcriptase (Promega). Quantitative PCR was carried out using
SYBR Green containing SensiMix (Bioline) and CFX96 Real-
Time PCR detection system (BioRad). Assay conditions were as
follows: 10 minute initial denaturation at 95uC and 40 cycles of 15
seconds at 95uC, 15 seconds at 60uC and 15 seconds at 72uC. The
PCR mix contained 250 nM of each primer (Table S1) and 5–-
30 ng of cDNA. The reactions were performed in triplicates and
the results were analyzed using qbasePLUS (Biogazelle) with b-
actin as the housekeeping gene.
Statistical Analysis
For the morphology-based evaluation of J1 mESCs maintained
in various treatments for over a month, the total number of
colonies and the total number of pluripotent-like colonies were
quantified in five non-overlapping fields. Average data for samples
were analyzed with GraphPad Prism 5 software using one-way
ANOVA and Dunnett post-hoc analysis for comparing LIF-
treated mESCs with the remaining treatments. For MilliTrace
Nanog GFP Reporter mESCs, data from two independent
experiments was analyzed as described above for J1 mESCs.
Results
SB-216763 Induces b-catenin Mediated-transcription in a
Dose-dependent Manner
SB-216763 is a potent inhibitor of both GSK3a and GSK3b,
and can induce robust expression of a b-catenin reporter gene in
HEK293 cells [39–41]. As expected, HEK293 cells treated with
1–20 mM SB-216763 exhibited a dose-dependent increase in
Super TOPFlash activity (Figure 1; top). A similar TOPFlash
dose-response for SB-216763 was also observed in J1 mESCs co-
cultured with MEFs (Figure 1; bottom). BIO induced maximal
activation of TOPFlash activity at a dose of 1 mM in HEK293 cells
(1230-fold) and 5 mM in J1 mESCs (55-fold). The reduction in
TOPFlash activation observed for 3–10 mM BIO in HEK293 cells
is very likely associated with the toxic effects we observed in the
serum-free Opti-MEM treatment media; 10 mM BIO also
appeared to reduce the proliferation of J1 mESCs, resulting in
decreased reporter activity. CHIR-99021 was the most potent
inducer of TOPFlash activity in HEK293 cells (2130-fold at
10 mM) and J1 mESCs (103-fold at 10 mM).) Two mM BIO and
3 mM CHIR-99021 have been previously tested in mESC
pluripotency assays by other groups [34,35]. Our results show
that the activation of TOPFlash by 2 mM BIO (9.2-fold) and 3 mM
CHIR-99021 (24-fold) is comparable to activation by 10–20 mM
SB-216763 (7.3- and 45-fold, respectively).
Comparison of the two panels in Figure 1 suggests that the J1
mESCs were less responsive to the GSK3 inhibitor treatments.
However, the results for J1 mESCs and HEK293 cannot be
directly compared because the J1 mESCs were treated in the
presence of 15% ES-FBS, whereas HEK293 cells were treated in
serum-free Opti-MEM. We performed the TOPFlash assay in J1
mESCs in serum-containing medium to allow for an accurate
assessment of the level of b-catenin activation observed under
normal mESC culture conditions. Furthermore, MEFs are also
known to secrete Wnt proteins, which could activate b-catenin in
mESCs [34,42]. This would increase reporter activity in the
vehicle treated samples and therefore proportionally reduce the
fold-activations in the treated samples. Consistent with previous
results, we also show that 100–10,000 U/ml of LIF does not
further activate the TOPFlash reporter in J1 mESCs [43].
Specifically, this suggests that the LIF supplement does not induce
secretion of canonical Wnt proteins from mESCs or MEFs.
SB-216763 Maintains mESCs with a Pluripotent-like
Morphology
The role of b-catenin in mESC pluripotency and self-renewal is
implicated by several genetics-based studies [13,25,32]. However,
the ability of GSK3 inhibitors to maintain pluripotency for an
extended period is less clear [32,34–36]. Thus, we investigated
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entiated, pluripotent-like morphology in long-term culture. As
expected, control mESCs maintained with LIF grew as compact
colonies whose borders had high optical density and appeared as
shadows and highlights on a Hoffman Modulation Contrast
microscope or as glowing edges under a phase-contrast microscope
(Figure 2A). These characteristics are widely accepted as a strong
indicator of the pluripotent state (e.g., [44]). In a preliminary dose-
response experiment, we found that LIF-free mESC medium and
doses lower than 10 mM of SB-216763 were unable to maintain
mESCs in a pluripotent-like state, whereas 30 mM SB-216763
yielded compact pluripotent-like colonies, which were much
smaller and fewer in number (data not shown). This latter finding
is consistent with observations of other groups that high doses of
GSK3 inhibitors attenuate mESC proliferation [13,32,35]. Thus,
to circumvent proliferation rate-related issues, we further investi-
gated whether 10–20 mM SB-216763 could maintain mESCs in a
pluripotent state.
J1 mESCs were cultured in LIF-free mESC medium or medium
supplemented with LIF (1000 U/ml) or 10, 15 and 20 mM SB-
216763. The cultures were passaged in parallel every 3–4 days for
over a month. We observed that all doses of SB-216763 (10, 15,
and 20 mM) and LIF maintained mESCs in a pluripotent-like
state, and the mESCs cultured without any supplements (LIF-free)
differentiated within two weeks (Figure 2A). MESC colonies in
these samples were rated for pluripotency-like morphologies
between passages 4 to 7 (weeks 2–4) (Figure 2B). Generally, we
found that 80% of the colonies in 15 mM and 20 mM were rated as
being pluripotent-like based on our criteria. LIF and 10 mM SB-
216763 also maintained colonies in a pluripotent-like state, but
there was less reliability in maintaining a high number of
pluripotent-like mESC colonies between passages 4–7 in this
experiment. As with 30 mM SB-216763 treatment, 20 mM SB-
216763 yielded slightly fewer colonies which were compact and
generally smaller than those seen with 10 mM SB-216763
(Figure 2C). Moreover, we observed that SB-216763 precipitated
from the culture medium at doses $20 mM. The percentage of
pluripotent-like colonies was not significantly different between
LIF-treated mESCs and any of the SB-216763-treated samples
(Figure 2C). For one of these follow-up experiments, the 10 mM
SB-216763 and LIF treated cultures were continued for an
additional month. At the end of the two month period, mESCs
maintained with 10 mM SB-216763 were morphologically indis-
tinguishable from those maintained with LIF (data not shown).
These results suggest that SB-216763 can maintain mESCs with a
pluripotent-like morphology in long-term culture.
MESCs Maintained with SB-216763 for Greater than One
Month Express Pluripotency-Promoting Genes at Levels
Comparable to LIF-treated mESCs
We next determined the effects of long-term maintenance of
mESCs with SB-216763 on the expression of pluripotency-specific
genes. RNA transcripts for Oct4, Sox2, Nanog, and the b-catenin
regulated gene Lrh-1, were quantified in mESCs maintained with
LIF or 10 mM SB-216763 for one month [3,7,9–13]. We found
that all four of these genes were expressed at high levels in both
mESC cultures (Figure 3). However, expression of Sox2 and Lrh-1
was nearly 3-fold higher in SB-216763-treated mESCs compared
to the LIF controls. Additionally, Nanog expression was moder-
ately higher in SB-216763-treated cultures compared to the LIF
control, whereas Oct4 expression was about 50% lower. Embryoid
bodies (EB) prepared from these cultures after withdrawal of LIF
or SB-216763 generally exhibited reduced expression of the
pluripotency markers. These results suggest that the effects of SB-
216763 on pluripotent-specific gene expression are reversible
(Figure 3).
Our qPCR results were subsequently confirmed by immunocy-
tochemistry for Oct4 and Nanog, the two most widely used
immunocytochemistry markers for pluripotent stem cells. LIF and
all doses of SB-216763 (10, 15, and 20 mM) yielded compact
Figure 1. SB-216763, BIO and CHIR-99021 induce expression of a b-catenin reporter gene in a dose dependent manner. HEK293 cells
(top panel) and J1 mESCs (bottom panel) were electroporated with the Super TOPFlash and pGL4.73 Renilla luciferase reporters. The cells were
treated in quadruplicate wells with a vehicle control (0.1% DMSO) or the indicated doses of LIF, SB-216763, BIO, or CHIR-99021 for 24 hours. Cell
lysates were then assayed for dual luciferase reporter activity. Firefly luciferase activity was normalized to Renilla luciferase activity for each sample,
and then all results were normalized to the vehicle control. Data are expressed as the mean 6 SEM from three independent trials.
doi:10.1371/journal.pone.0039329.g001
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cellular Nanog was carried out on an independent culture that was
grown for more than a month in the presence of LIF or 10 mM
SB-216763. Surprisingly, Nanog immunostaining was distinctly
more homogenous in the SB-216763-treated samples compared to
the LIF-treated controls (Figure 5).
SB-216763, Unlike BIO and CHIR-99021, can Maintain J1
mESCs in a Pluripotent State for More than a Month
As shown previously, treatment of J1 mESCs for 24 hours under
the conditions described here yielded TOPFlash reporter activity
that was comparable between 2 mM BIO, 3 mM CHIR, and
10 mM SB-216763 treatments (Figure 1). Thus, we compared the
ability of 2 mM BIO and 3 mM CHIR-99021 to sustain long-term
cultures of J1 mESCs with parallel cultures maintained with 10–
20 mM SB-216763 and LIF [34,35]. The samples were stained for
alkaline phosphatase (AP) activity, another well-known marker for
pluripotent mESCs, on days 10, 20 and 30. As expected, vehicle
treated samples differentiated by Day 10 and no colonies or AP
positive cells were detected by day 20. Consistent with a previous
report, BIO was able to maintain J1 mESCs with a pluripotent-like
morphology for at least 10 days (Figure 6; [34]). By day 20, BIO
samples had differentiated and after 30 days they were devoid of
any pluripotent-like colonies. In general, 3 mM CHIR-99021
maintained pluripotent-like mESCs for a longer period of time
compared to BIO, but most of the colonies were no longer tightly
packed by day 20. After 30 days, the AP staining and colony
morphology of CHIR-99021 samples resembled the differentiated
BIO samples at day 20. In contrast, LIF and SB-216763 treated
Figure 2. J1 mESCs maintained with SB-216763 have a pluripotent-like morphology. (A) Phase-contrast images of mESCs treated with LIF
(1,000 U/mL), or 10, 15, and 20 mM SB-216763 for more than a month. All doses of SB-216763 maintained mESCs as compact, elliptical or circular
colonies characteristic of pluripotent cells. Morphology for mESC colonies maintained with SB-216763 was comparable to those in LIF supplemented
medium. Scale bars represent 100 mm. (B) Twenty thousand mESCs from each treatment were seeded in a 6-well chamber at each passage and
monitored for the percentage of pluripotent-like colonies two days after each passage. Data are expressed as the mean of five fields analyzed 6 SEM.
The percentage of pluripotent-like colonies in vehicle-treated cultures was significantly different from 15 mM and 20 mM SB-216763 samples at
passage 4 (p,0.05) and from all treated samples from passage 5 onwards (p,0.05). (C) The average number of the total colonies and total
pluripotent-like colonies observed between passages 4–7. The number of pluripotent-like colonies in vehicle-treated cultures was significantly lower
than that for all other treatments (p,0.05). None of the SB-216763-treated samples were significantly different from LIF-treated mESCs for either the
total number of colonies or the total number of pluripotent-like colonies.
doi:10.1371/journal.pone.0039329.g002
Figure 3. J1 mESCs maintained with 10 mM SB-216763 or LIF
for more than a month express Oct4, Nanog, Sox2 and Lrh-1.
The graph also shows expression of these markers in EBs derived from
month-old LIF and SB-216763 mESCs. SYBR Green qPCR results for these
four genes were normalized to b-actin housekeeping gene using
qbasePLUS software. SB-216763 treated mESCs expressed Lrh-1 and
Sox2 about 3-fold higher than LIF treated mESCs. Nanog expression was
also moderately higher in the SB-216763-treated mESCs, whereas Oct-4
expression was nearly 50% higher in LIF-treated mESC. Expression of
these genes in differentiated cells was generally lower than the mESCs
maintained with either LIF or 10 mM SB-216763. The data are average 6
S.D. of technical replicates from one of the two experiments.
doi:10.1371/journal.pone.0039329.g003
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(Figure 6). An independent experiment further demonstrated that
10 mM SB-216763 can sustain AP-positive mESC colonies for at
least up to 60 days (Figure 6; Day 60). To our knowledge, this
makes SB-216763 the first GSK3 inhibitor that can maintain
mESCs in a pluripotent state for at least two months.
SB-216763 can Maintain MilliTrace Nanog GFP Reporter
mESCs in a Pluripotent State
ToconfirmthatourresultswerenotspecifictoJ1mESCs,wealso
maintained MilliTrace Nanog GFP Reporter mESCs with SB-
216763 for one month. These mESCs express GFP under the
control of the mouse Nanog promoter. Consistent with our
expectations, MilliTrace mESCs maintained with 10 mM SB-
216763 were morphologically indistinguishable from LIF-treated
controls and exhibited robust GFP expression (Figure 7A). All the
mESC colonies in LIF and 10 mM SB-216763 treated cultures
expressed GFP at high levels and for the most part GFP distribution
was homogeneous in these colonies. Scoring of GFP fluorescence
intensityandhomogeneousdistributionofGFPshowedthatmESCs
maintained with 10 mM SB-216763 were statistically not different
from those maintained with LIF (Figure 7B). Some GFP expression
was visible in nearly half of the mESC colonies grown without any
supplements (LIF-free), but the expression was hardly ever uniform
in these colonies. The LIF (-) panel in Figure 6A shows one of the
GFP expressing colonies. We also observed a higher level of
homogeneous GFP expression in the MilliTrace Nanog GFP
Reporter mESCs maintained with 1 mM and 3 mM SB-216763
Figure 4. J1 mESCs maintained with SB-216763 for one month express the pluripotency marker Oct–4. Cultures were maintained
continuously with various doses of SB-216763 or LIF for 1 month and then immunostained for Oct–4. SB-216763 precipitated at doses $20 mM, and
some of these particulates are visible in the phase-contrast images as black spots that fluoresced intensely green when excited at ,480 nm. Scale
bars represent 100 mm.
doi:10.1371/journal.pone.0039329.g004
Figure 5. Expression of Nanog pluripotency marker is more homogeneous in J1 mESCs maintained with 10 mM SB-216763. MESCs
maintained with either LIF or 10 mM SB-216763 for more than a month yielded pluripotent-like colonies. Immunostaining revealed that Nanog
expression (green fluorescence) was homogeneous in mESC colonies maintained with SB-216763, whereas LIF-treated mESC colonies often displayed
incomplete Nanog staining. Three representative colonies from each treatment are shown. Scale bars represent 40 mm.
doi:10.1371/journal.pone.0039329.g005
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dosesofSB-216763failedtopromotepluripotent-likemorphologies
in the J1 mESCs (data not shown). It is possible that the MilliTrace
NanogGFPReportermESCsaremoreresponsivetoSB-216763,or
that these mESCs are easier to maintain in a pluripotent state. As
with Nanog immunostaining of J1 mESCs, the MilliTrace Nanog
GFP Reporter mESCs maintained with 10 mM SB-216763 were
more homogeneously labeled for GFP than the mESCs maintained
Figure 6. SB-216763, unlike BIO and CHIR-99021, can maintain J1 mESCs in a pluripotent state for at least two months. J1 mESCs co-
cultured with MEFs were maintained continuously with vehicle (0.1% DMSO), 1,000 U/ml LIF, 10 or 20 mM SB-216763, 2 mM BIO, or 3 mM CHIR-99021.
The cultures were passaged in parallel and 20,000–50,000 mESCs were plated on new MEF-covered 6-well plates every 3 days. A duplicate plate was
stained for alkaline phosphatase (AP) activity at days 10, 20, and 30. Shown are representative images from one of two independent trials. Day 60
images were obtained from an independent culture maintained with vehicle (0.1% DMSO), 1,000 U/mL LIF, or 10 mM SB-216763. AP staining on day
60 was carried out on samples from a single trial. The scale bar shown in the day 10 vehicle image represents 100 mm and all images are presented at
the same scale.
doi:10.1371/journal.pone.0039329.g006
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that 10 mM SB-216763 can maintain at least two independently-
derived mESC lines in a pluripotent state for more than a month.
MESCs Maintained with 10 mM SB-216763 can
Differentiate into All Germ Layers
One of the defining characteristics of pluripotent cells is their
ability to differentiate into all three lineages. Thus, we tested
whether J1 mESCs maintained with SB-216763 retained their
multi-differentiation potential by generating cardiac-like cells and
neurons, and by monitoring expression of early stage markers of
the three germ layers in EBs. MESCs maintained with 10 mM SB-
216763 for more than a month differentiated into EBs as
efficiently as those maintained with LIF. As shown in Figure 3,
expression of pluripotency-promoting markers is lower in both EB
samples, and indistinguishable from each other.
EBs derived from LIF- and SB-216763-supplemented mESCs
readily differentiated into cardiac-like cells. The yield and
appearance of cardiac-like cells were very similar between the
two samples (Figure 8A). The autonomously contracting cells
within EBs were first detected 4 days after EB attachment, which
peaked on day 6 and gradually decreased thereafter (Figure 8A).
Furthermore, the cardiac-like cells derived from these two mESC
cultures appeared to be similar for EB size, contracting cluster size
and the frequency of contractions (data not shown).
EBs differentiated into neurons using all-trans retinoic acid and
the 42/4+ protocol also yielded similar morphologies and
expression of MAP-2 (a marker of mature neurons) [38]. Neurites
were apparent two days after attachment (10 days after EB
formation) and neurite arborization increased for another week.
Immunocytochemistry for MAP-2 18 days after EB formation
showed that the yield of neurons and their morphology were not
dependent on the supplement used to maintain mESC in a
pluripotent state (Figure 8B).
We also analyzed expression of the early-stage markers for the
three germ layers in EBs, cardiac-like cells and neuronal cells. Our
results show that expression of all the lineage-specific genes is
comparable within each respective cell type regardless of whether
the mESCs were maintained with LIF or 10 mM SB-216763. The
ectodermal/neuroectodermal markers, Nestin and Pax6, were
expressed at the highest levels in the neuronal sample (8 days after
EB formation) and their expression levels were comparable
between neurons derived from mESCs maintained with LIF and
SB-216763 (Figure 8C). Expression of Tuj1 was nearly four-fold
higher in pluripotent mESCs maintained with SB-216763
compared to mESCs maintained with LIF (Figure 8C). This
pattern of Tuj1 expression may be expected based on the previous
report that TWS119, a GSK3 inhibitor, can direct differentiation
of mESCs into neurons without EB formation [45].
Quantification of three mesodermal markers – Nkx2.5,
Brachyury, and Goosecoid (GSC) – in mESCs, EBs, cardiac-like
and neuronal cells showed only minor differences between the two
treatments. Regardless of the pluripotency maintenance supple-
ment, Brachyury expression was the highest during mESC and EB
stages. The high level of Brachyury expression in mESCs was a
surprising result. Brachyury is an early stage marker of mesoderm,
and its increased expression in predominantly pluripotent mESC
cultures possibly suggests that spontaneously differentiating cells in
the culture are following the normal process at these initial stages
[46]. Nkx2.5 expression was relatively low but increased modestly
from mESCs to EBs to cardiac-like cells regardless of whether the
mESCs were maintained in LIF or SB-216763 (Figure 8D).
Among the endodermal markers, alpha-fetoprotein (AFP) was
expressed at the highest level in cardiac-like cells, and at modest
Figure 7. 10 mM SB-216763 maintains MilliTrace Nanog GFP Reporter mESCs in a pluripotent-like state for more than a month. (A)
GFP fluorescence in representative colonies from each treatment. (B) Mean pluripotency rating of two independent experiments 6 SEM. Forty
colonies were rated from each condition for the intensity and uniformity of GFP fluorescence after a month in culture. Statistical analysis revealed that
the cultures maintained with LIF, 3 mM and 10 mM SB-216763 were significantly different than mESCs maintained without LIF.
doi:10.1371/journal.pone.0039329.g007
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39329Figure 8. J1 mESCs maintained with SB-216763 retain their ability to differentiate into all three germ layers. Cultures maintained with
10 mM SB-216763 or LIF for more than one month were differentiated into (A) cardiac-like cells, (B) neurons, and EBs expressing transcript markers for
(C) ectoderm or neuroectoderm, (D) mesoderm, and (E) endoderm. (A) The number of flattened autonomously contracting EBs was assessed every
other day after the 4-day old EBs were transferred to a 24-well chamber (one EB/well). More than 25% of the 20 EBs analyzed per condition showed
some level of autonomous contraction. (B) Neurons were stained for the neuronal marker gene MAP-2 by immunocytochemistry 16 days after EB
formation. Scale bars represent 40 mm. (C-E) EBs prepared from mESCs maintained with either 10 mM SB-216763 or LIF conditions expressed early-
stage transcript markers for all three germ layers. Data are representative from one experiment 6 SD.
doi:10.1371/journal.pone.0039329.g008
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GATA4 in both neuronal samples (Figure 8E). This may support
the presence of astrocyte precursors and or specific neuronal
precursors [47,48]. Foxa2 expression was very low in all cell types
(Figure 8E). A comparison of samples derived from LIF- and SB-
216763-treated mESCs revealed only minor differences in
expression levels of these three endodermal markers.
These results show that mESCs maintained in 10 mM SB-
216763 for more than a month can successfully differentiate into
cardiac-like cells and neurons, and can express germ line markers
in the differentiated cells at levels comparable to LIF-maintained
mESCs.
Discussion
The canonical Wnt pathway is essential for the development of
all animals [18,49,50]. In bilaterians, canonical Wnts usually lead
to sequestration of GSK3 and accumulation of b-catenin, which in
a context-dependent manner signals for proliferation, cell lineage
specification, and maintenance of the pluripotent and multipotent
states [15–18,51]. Thus, several groups have tested whether small
molecules that activate the canonical Wnt pathway and increase b-
catenin-mediated gene expression, can maintain stem cells in a
pluripotent state [32,34–36]. Here, we show that 10 mM SB-
216763, a GSK3 inhibitor, can maintain J1 and MilliTrace Nanog
GFP Reporter mESC lines in a pluripotent state for more than a
month. We have used four assays to support this conclusion: (1)
colony morphology, (2) expression of pluripotency markers and
pluripotency-associated genes, (3) effective differentiation into
cardiac-like and neuronal cells, and (4) expression of early-stage
markers in EBs representing all three germ layers. MESCs
maintained with 10 mM SB-216763 were indistinguishable or
slightly better than LIF treated mESCs for each of these assays.
The concentration of SB-216763 needed for optimal mainte-
nance of pluripotency in J1 mESCs also yielded robust activation
of the b-catenin reporter gene. In mESCs, b-catenin is thought to
mediate its actions through both its functions at the adherens
junction as well as the nucleus [32,52–54]. One of the well
characterized functions of b-catenin in the nucleus is its ability to
alleviate TCF3’s repression of pluripotency promoting genes
[12,26]. Chromatin-immunoprecipitation assays have shown that
the vast majority of TCF3 target promoters are also occupied by
Oct4, Sox2 and Nanog [26,27]. Deletion of TCF3 increases levels
of Oct4 and Nanog, and also eliminates the need for Wnt3a or
GSK3 inhibition for maintenance of self-renewal [26,27]. One of
the direct targets of this de-repression is Lrh-1 [13]. Expression of
Lrh-1 appears to be dependent on b-catenin, and in turn Lrh-1
can promote expression of pluripotency transcription factors Oct-4
and Nanog [13]. Consistent with this, we found that long-term
maintenance of mESCs in a pluripotent state with 10 mM SB-
216763 induces higher levels of Lrh-1 compared to the parallel
mESC cultures maintained with LIF (Figure 5). These observa-
tions support the idea that the b-catenin/Lrh-1 signaling axis is
important for maintenance of pluripotency by b-catenin activators
such as SB-216763.
Several lines of genetic evidence suggest that b-catenin is an
important determinant of self-renewal and maintenance of the
pluripotent state [13,25,32,33,54]. Thus, small molecule inhibitors
of GSK3 that block degradation of b-catenin should be able to
promote pluripotency. The earliest evidence that a GSK3 inhibitor
could promote pluripotency was demonstrated with BIO. BIO
induced expression of Oct-4, Rex-1 and Nanog in both human and
mouse ESCs and supported pluripotency for at least 1 week [34].
However,theseeffectscannotbeconsideredGSK3-specificbecause
thedosesusedforBIOwerenearly1000-foldhigherthanBIO’sIC50
for GSK3 of 5nM and were approximately 10-fold higher than
BIO’s IC50 for other kinases such as CDK1, CDK2, and CDK5
[55]. Moreover, two other groups have suggested that these effects
are short-lived and not suitable for long-term maintenance of stem
cells in a pluripotent state [13,35]. More selective GSK3 inhibitors
suchasCHIR-99021andbisindolylmaleimides alsofail tomaintain
mESCs in a pluripotent state for the long-term by themselves
[32,34–36]. We initially tested SB-216763 because it is a fairly
selective and potent inhibitor of GSK3. For example, in an in vitro
assay, 10 mM SB-216763 reduced b-catenin activity to ,5%
without dramatically affecting 24 other kinases tested [56]. This
raises the possibility that SB-216763 may be mediating some of its
pluripotencypromotingeffectsthroughotherkinases.CHIR-99021
and SB-216763 belong to different classes of compounds and
thereforethesedrugsbindtodifferentsetsofnonspecifictargetswith
varying affinities; CHIR-99021 is an aminopyrimidine whereasSB-
216763is anarylindolemaleimide [41,56–58]. Comparisonof these
two compounds for their effect on a panel of kinases showed that
CHIR-99021 is more selective than SB-216763, but both com-
pounds also inhibit other kinases: 1 mM CHIR-99021 can reduce
activity of CDK2, PLK1 and MELK by .50%, while 10 mM SB-
216763 reduces activity of CDK2, ERK8, DRYK1A, PIM3,
SRPK1, HIPK2 and HIPK3 by .50% [41]. Our prediction is that
the off-target effects of SB-216763 contribute to pluripotency
maintenance, while the off-target effects of BIO, CHIR-99021 and
bisindolylmaleimides do not. However, there is no evidence to
supporttheideathattheseoff-targeteffectsaremoreimportantthan
the GSK3 inhibition (e.g., Figure 6). We therefore suggest that SB-
216763’soff-targeteffectsworksynergisticallywithGSK3inhibition
topromotepluripotency.Forexample,itispossiblethatinhibitionof
homeodomain-interacting protein kinase 2 (HIPK2) could enhance
SB-216763’s ability to maintain pluripotency. HIPK2 can phos-
phorylateb-cateninandtargetitfordegradationinamannersimilar
to GSK3 [59]. In the case of mouse epidermal stem cells, loss of
HIPK2resultsinanincreaseincellproliferationrate[60].Thus,SB-
216763 mediated inhibition of HIPK2 (85% inhibition at 10 mM
[41]) could work synergistically with GSK3 inhibition. Pharmaco-
logical evaluation of this GSK3/HIPK2 dual inhibition hypothesis
cannot be explored right now as HIPK2 specific inhibitors are not
yet commercially available.
There is an added level of complexity with GSK3 inhibitors and
GSK3 mutants. GSK3a and GSK3b are integral components of
several pathways and attenuation of GSK3 function affects all of
those pathways [61,62]. From these GSK3-associated signaling
pathways, the b-catenin pathway is considered to be most
important for the maintenance of pluripotency [13,32]. Consis-
tently, our results demonstrate that the SB-216763 concentrations
needed for optimal growth and self-renewal of pluripotent mESCs
robustly activate b-catenin reporter gene in mESCs (Figure 1).
However, our results also show that activation of b-catenin alone is
not sufficient for maintenance of pluripotency (Figures 1 and 6). As
discussed above, we recognize that almost all small molecules have
off target effects and that some of these other targets could also
contribute to SB-216763’s ability to maintain mESCs in a
pluripotent state. Further evaluation of the role of these other
SB-216763 target proteins in maintenance of pluripotency can
enhance our knowledge of the signal transduction pathways that
regulate cell fate decisions. Nonetheless, our results unequivocally
demonstrate that SB-216763 can maintain mESCs co-cultured
with MEFs in a pluripotent state for up to two months in the
absence of exogenous LIF.
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